Helpful does not mean risk-free
Saying that people lost weight is not enough. We also need to know how they felt. Did they have nausea? Did anyone have to stop treatment? How often did this happen in each group?
Results from a few studies cannot reveal every problem that may emerge after many years. Also, not every health problem during a study is necessarily caused by the substance being taken.
A vial label is not a guarantee
In Australia, an official laboratory tested a product sold as retatrutide. It contained a different substance: semaglutide. No retatrutide was found. [11]
This example shows that a product's contents may differ from the name on its label. Retatrutide study results therefore cannot be applied to every vial bearing that name. [11]
What does medicine approval mean?
An approved medicine has a defined composition, uses and risk information. That does not mean it has no side effects. Semaglutide and tirzepatide are present in approved medicines; retatrutide remains investigational. [16] [25] [6]
The doctor considers conditions, other medicines and the treatment goal. Pregnancy, a planned procedure and previous problems with similar products also matter. We describe the details separately for each substance.
Where does this information come from?
Show sources and how they were checked
- TGA: badanie produktu sprzedawanego jako retatrutyd
Australian regulator announcement · 14.09.2026 · full page. Accessed: 02.11.2026.
- FDA: Concerns with Unapproved GLP-1 Drugs
US regulator announcement · full page. Accessed: 02.11.2026.
- Lilly: What to know about retatrutide
Manufacturer information · October 2026 · full page. Accessed: 2 November 2026.
- EMA: Wegovy — polska informacja o produkcie
EU regulator · updated 26 October 2026 · selected indication, safety and leaflet sections reviewed, not the whole PDF. Accessed: 2 November 2026.
- EMA: Mounjaro — informacja o produkcie
EU regulator · updated 21.09.2026 · English safety sections and patient leaflet read, not the entire PDF. Accessed: 02.11.2026.